Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases

Phase 2

Completed

• Conditions: Liver Metastasis; Colorectal Neoplasms; Liver Neoplasms; Neoplasm Metastasis

• Registration Number: NCT00068068
• Lead Sponsor: Light Sciences LLC

Brief Summary

The purpose of this study is to determine whether the Litx platform is safe and effective in the treatment of liver metastasis arising from colorectal cancer. Litx is a next-generation photodynamic therapy platform in which the drug, talaporfin sodium (LS11), is activated by light from the light-emitting diode (LED)-based light infusion device, inserted directly into the tumor through the skin prior to treatment.

Detailed Description

Patients that provide Informed Consent and satisfy the Eligibility Criteria will undergo CT or ultrasound guided percutaneous placement of a single, two, three, or four light infusion devices depending on their tumor characteristics. No more than 4 light sources will be used at a single treatment. The light infusion devices may be used in a single lesion or in multiple lesions.

Following radiographic confirmation of light infusion device placement, patients will receive an intravenous dose of LS11 at 40 mg/m². One hour following completion of LS11 administration, delivery of 200 J/cm light energy will begin. The light infusion device will then be manually removed and the patients will be observed for acute complication of light infusion device removal. Precautions for protection from external light exposure should be instituted beginning with the LS11 administration and be maintained as defined throughout the study period. On day 30+5 the patient will undergo clinical assessment and the tumor mass will be imaged using contrast enhanced spiral CT for determination of volume and radius of the tumor size, as well as tumor necrosis. The patient may then receive 5-FU and/or leucovorin + either irinotecan or oxaliplatin standard chemotherapy at day 30 visit. All patients, with or without chemotherapy at day 30, will undergo final clinical assessment and final tumor imaging evaluation using contrast CT at day 60+5 of Litx treatment.

Study Timeline

• Study First Submitted: 2003-09-04
• Study First Submitted QC: 2003-09-05
• Study First Posted: 2003-09-08
• Study Start: 2003-10
• Status Verified: 2006-09
• Last Update Submitted: 2006-09-18
• Last Update Posted: 2006-09-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (6)

HealthOne Alliance/Presbyterian St. Lukes Medical Center; 🇺🇸 Denver, Colorado, United States

Eastern Carolina University, School of Medicine; 🇺🇸 Greenville, North Carolina, United States

Allegheny General Hospital; 🇺🇸 Pittsburgh, Pennsylvania, United States

Virginia Mason Medical Center; 🇺🇸 Seattle, Washington, United States

University of Pennsylvania / Department of Radiation Oncology; 🇺🇸 Philadelphia, Pennsylvania, United States

University Hospital Frankfurt, Johann Wolfgang Goethe-University; 🇩🇪 Frankfurt am Main, Germany